Teva Pharmaceutical Industries Ltd. has licensed an oral PARP inhibitor originally developed by Cephalon to Fortress Biotech company, Checkpoint Therapeutics, Inc. one of several subsidiary companies of Fortress Biotech, Inc. Checkpoint will obtain exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, oral PARP (poly ADP-ribose polymerase) inhibitor, CEP-9722, which is in early clinical development for solid tumors.
The small molecule selective inhibitor of PARP-1 and PARP-2 enzymes, CEP-9722, will be developed by Checkpoint as a monotherapy and...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

